# Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

> **NCT02961218** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 49 (actual)

## Conditions studied

- Sickle Cell Anemia

## Interventions

- **DRUG:** ACZ885
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02961218
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-05
- **Primary completion:** 2019-06-27
- **Final completion:** 2020-04-27
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02961218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02961218, "Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02961218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*